Scholarlink

Abstract <p>Trimethoprim (TMP) is a reversible inhibitor of the prokaryotic enzyme dihydrofolate reductase (DHFR) used for the treatment or prophylaxis of bacterial infections. [<sup>11</sup>C]trimethoprim ([<sup>11</sup>C]TMP) is a positron emission tomography (PET) imaging isotopologue of TMP. TMP binds with 30,000-fold greater affinity to bacterial DHFR over the homologous mammalian enzyme <i>in vitro</i>, suggesting [<sup>11</sup>C]TMP may selectively accumulate in tissues with cells expressing bacterial DHFR. This study characterizes the biodistribution and dosimetry of [<sup>11</sup>C]TMP, informing its use in imaging bacterial infections and tracking mammalian cells expressing eDHFR as a reporter gene.</p> Methods <p>Four males with suspected infection, aged 59 ± 10&#xa0;years old (mean ± SD) received 3 serial PET/CT scans after injection of 346 ± 305&#xa0;MBq (range 129–797&#xa0;MBq) of [<sup>11</sup>C]TMP. Organ activities were measured in MIM v6.7, including brain, kidneys, spleen, liver, heart, lungs, bladder, intestines, gallbladder, pancreas, thyroid, and red marrow. Dosimetry calculations were performed in Olinda | EXM v1.1. Additionally, a dynamic whole-body PET/CT scan was performed on a separate participant. The associated trial was registered as NCT03424525.</p> Results <p>[<sup>11</sup>C]TMP injections were well tolerated with no adverse events. The average injected activity of 346&#xa0;MBq of [<sup>11</sup>C]TMP yielded an estimated average dose of 4.9&#xa0;mSv in the highest uptake organ (liver), 4.1&#xa0;mSv in the spleen, and an effective dose of 1.6&#xa0;mSv. Suspected sites of infection displayed uptake above background.</p> Conclusion <p>[<sup>11</sup>C]TMP PET was safe and demonstrated low background uptake in most tissues. The data suggests feasibility for evaluation of varied bacterial infections, including musculoskeletal infections. Absorbed doses allow multiple [<sup>11</sup>C]TMP PET scans each year within Radioactive Drug Research Committee (RDRC) limits, potentially enabling monitoring of infections and treatment response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

First-in-Human Biodistribution and Dosimetry of [11C]Trimethoprim

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月22日

查看全文
  • Anthony J. Young,
  • Robert K. Doot,
  • Joshua K. Cho,
  • Jonathan M. Pham,
  • Alvaro A. Ordonez,
  • Andres F. del Castillo,
  • Tiffany L. Dominguez,
  • Supritha Dugyala,
  • Erin K. Schubert,
  • Hsiaoju Lee,
  • Austin R. Pantel,
  • Robert H. Mach,
  • David A. Mankoff,
  • Mark A. Sellmyer

摘要

Abstract

Trimethoprim (TMP) is a reversible inhibitor of the prokaryotic enzyme dihydrofolate reductase (DHFR) used for the treatment or prophylaxis of bacterial infections. [11C]trimethoprim ([11C]TMP) is a positron emission tomography (PET) imaging isotopologue of TMP. TMP binds with 30,000-fold greater affinity to bacterial DHFR over the homologous mammalian enzyme in vitro, suggesting [11C]TMP may selectively accumulate in tissues with cells expressing bacterial DHFR. This study characterizes the biodistribution and dosimetry of [11C]TMP, informing its use in imaging bacterial infections and tracking mammalian cells expressing eDHFR as a reporter gene.

Methods

Four males with suspected infection, aged 59 ± 10 years old (mean ± SD) received 3 serial PET/CT scans after injection of 346 ± 305 MBq (range 129–797 MBq) of [11C]TMP. Organ activities were measured in MIM v6.7, including brain, kidneys, spleen, liver, heart, lungs, bladder, intestines, gallbladder, pancreas, thyroid, and red marrow. Dosimetry calculations were performed in Olinda | EXM v1.1. Additionally, a dynamic whole-body PET/CT scan was performed on a separate participant. The associated trial was registered as NCT03424525.

Results

[11C]TMP injections were well tolerated with no adverse events. The average injected activity of 346 MBq of [11C]TMP yielded an estimated average dose of 4.9 mSv in the highest uptake organ (liver), 4.1 mSv in the spleen, and an effective dose of 1.6 mSv. Suspected sites of infection displayed uptake above background.

Conclusion

[11C]TMP PET was safe and demonstrated low background uptake in most tissues. The data suggests feasibility for evaluation of varied bacterial infections, including musculoskeletal infections. Absorbed doses allow multiple [11C]TMP PET scans each year within Radioactive Drug Research Committee (RDRC) limits, potentially enabling monitoring of infections and treatment response.